NEW ORAL ANTICOAGULANTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE
https://doi.org/10.21518/2307-1109-2015-2-51-57
Abstract
About 10% of the adult population is diagnosed with chronic kidney disease (CKD), and its presence is associated with a high risk of developing cardiovascular diseases including ventricular fibrillation (VF). The long-term monitoring of patients has found a clear association between the degree of renal failure and risk of VF development. ARIC (1) study showed that a relative risk of VF development in patients with glomerular filtration rate (GFR) 15-29 ml/min was 3.2 (95% CI 2.0-5.0), and in patients with normal GFR 1.3 (95% CI 1.1-1.6), p < 0.0001. GFR reduction is an independent predictor of VF development. The mechanism underlying the link between renal failure and risk of VF development is not fully clear.
About the Author
E. P. Panchenko
Myasnikov Clinical Cardiology Institute FGBU RKNPK of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Dr.scient.med, Professor
References
1. Alonso et al. Сhronic kidney disease is associated with the incidence of atrial fibrillation. The Atherosclerosis risk in communities (ARIC) study. Circulation, 2011. 123: 2946-2953.
2. Go et al. Impact of proteinuria and glomerular filtration rate on risk of thromboem-bolism in AF. Circulation, 2009. 119: 1363-1369.
3. Reinecke et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am SocNephrol, 2009. 20: 705-711.
4. Ziad Hijazi et al. Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. Circulation, 2014. 129: 961-970.
5. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L.Eur Heart J. 2012. 33(22): 2821-30.
6. Connolly SJ et al. for the AVERROES Steering Committee and investigetors. Apixaban in Patients with Atrial Fibrillation. NEnglJMed. 2011. 364: 806-817.
7. Patel et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation NEnglJMed.
8. 365(10):883-891.
9. K. Fox et al. Prevention of stroke and systemic embolism with rivaroxaban compared
10. with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. EurHeartJ, 2011. doi:10.1093/eurheartj/ehr342
11. Nielsen PB et al. Renal function and non-vitamin K oral anticoagulation in comparison with
12. warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol, 2014. DOI10.1007/s00392-014-0797-9.
13. Lega JC et al. Consistency of safety profileof new oral anticoagulants inpatients with renal failure. Thromb Haemost, 2014. 12(3): 337—43.
14. P.A. Reilly et al. The effect of dabigatran plasma concentration and patients characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. JACC, 2014. 63(4): 321-8.
15. H. Heidbuchel et al. European Heart Rhythm Association bPractical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013. 15:625-51.
16. Eikelboom JW et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation an analysis of the randomized evaluation of long-term anticoagulation therapy (RELY) trial. Circulation, 2011. 123: 2363-72.
17. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Российский кардиологический журнал, 2013. 4(102), приложение 3.
Review
For citations:
Panchenko E.P. NEW ORAL ANTICOAGULANTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE. Aterotromboz = Atherothrombosis. 2015;(2):51-57. (In Russ.) https://doi.org/10.21518/2307-1109-2015-2-51-57
Views:
1089
This work is licensed under a Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Email this article 